Lipo-protein apheresis and PCSK9-inhibitors

January 02, 2019

Research suggests a specific treatment for Homozygous Familial Hypercholesterolaemic (HoFH) pateints; a combination therapy with PCSK9-inhibitors (PCSK9-I) and lipoprotein-apheresis (LA) may have synergistic effects on circulating lipid and lipoprotein levels. The relationship with the treatment regimen mentioned above can be investigated further with larger datasets.

This review details the role of lipoprotein apheresis in the management of familial hypercholesterolaemia and discusses the potential advantages and disadvantages of its combination with PCSK9 inhibitors. Having impact on inflammation and related mediators, LA is also a potent therapeutic player. A large body of evidence is available to support this theory. On the contrary, only a few observations are available on PCSK9-I effects on inflammation.

It is quite clear that further investigation on possible direct and/or indirect pleiotropic effects of PCSK9-I on inflammatory molecules is necessary. Evidence on both arguments with regard to HoFH and HeFH are reported in short.
-end-
This article is Open Access. To obtain the article please visit http://www.eurekaselect.com/166623

Bentham Science Publishers

Related Lipoprotein Articles from Brightsurf:

Testing for a lipoprotein linked to heart risk is as effective as blood work
Elevated levels of a little-known lipoprotein in the blood that may put people at high risk of cardiovascular disease can be as accurately detected by genetic testing as by conventional laboratory measurement.

Study identifies the mechanism by which eating fish reduces risk of cardiovascular disease
Researchers of Universitat Rovira I Virgili and Harvard Medical School have demonstrated the association between the consumption of omega 3 and the reduction in the risk of suffering cardiovascular events through the analysis of lipoprotein samples from 26,034 women, the largest and most detailed study ever carried out.

High lipoprotein(a) levels in type 1 diabetes linked to cardiovascular disease
High blood levels of the lipid lipoprotein(a) in people with type 1 diabetes add to the already elevated risk of developing cardiovascular disease, researchers from Karolinska Institutet in Sweden report in a paper published in the prestigious journal Diabetes Care.

Analysis of studies into alcohol consumption in people with type 2 diabetes suggests
An meta-analysis of studies presented at this year's Annual Meeting of the European Association for the Study of Diabetes in Barcelona, Spain (Sept.

Study finds link between hypertension and air pollution
A new study soon to appear in the Faculty of Public Health's Journal of Public Health, published by Oxford University Press, suggests that air pollution and living in apartment buildings may be associated with an increased risk for dangerous conditions like heart disease, stroke, and type 2 diabetes.

Metabolomic profiling of antibody response to periodontal pathogens
At the 97th General Session & Exhibition of the International Association for Dental Research (IADR), held in conjunction with the 48th Annual Meeting of the American Association for Dental Research (AADR) and the 43rd Annual Meeting of the Canadian Association for Dental Research (CADR), Jaakko Leskela, University of Helsinki, Finland, gave an oral presentation on 'Metabolomic Profiling of Antibody Response to Periodontal Pathogens.'

Did cholesterol levels improve among us kids, adolescents?
This study examined cholesterol levels in children and adolescents in the US from 1999 to 2016.

Lipo-protein apheresis and PCSK9-inhibitors
This review aims to present the role of lipoprotein apheresis in the management of familial hypercholesterolaemia and discuss the potential advantages and disadvantages of its combination with PCSK9 inhibitors.It is quite clear that further investigation on possible direct and/or indirect pleiotropic effects of PCSK9-I on inflammatory molecules is necessary and to be expected.

Patients with high lipoprotein(a) levels may benefit from taking PCSK9 inhibitors
In the latest analysis from the FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk) trial, researchers found that PCSK9 inhibitors reduced lipoprotein(a) levels and that patients starting with higher Lp(a) levels appeared to derive greater absolute benefit from taking PSCK9 inhibitors.

Gene therapy for lipoprotein lipase deficiency yields promising results
During the first 18 months after treatment with alipogene tiparvovec, a gene therapy recently approved in Europe to treat lipoprotein lipase deficiency (LPLD), the first patient to receive the treatment had no abdominal pain or episodes of pancreatitis, following a history of 37 pancreatitis attacks.

Read More: Lipoprotein News and Lipoprotein Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.